Randomized phase II trial of sequential versus concurrent docetaxel and PS-341 (NSC 681239, IND 58443) [bortezomib] in previously treated non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 20 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.